{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:52:28Z","timestamp":1771649548516,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-334-4309"],"award-info":[{"award-number":["IN-US-334-4309"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12072-019-09974-z","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T15:44:20Z","timestamp":1567007060000},"page":"587-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium"],"prefix":"10.1007","volume":"13","author":[{"given":"Chung-Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Haga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Iwane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Kam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Yoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Ha","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ming","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin-Ho","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwai-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"For the REAL-C Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"9974_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"The Polaris Observatory HCV Collaborators","year":"2017","unstructured":"The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9974_CR2","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/14656566.2017.1400010","volume":"18","author":"CF Huang","year":"2017","unstructured":"Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Exp Opin Pharmacother. 2017;18:1867\u201374.","journal-title":"Exp Opin Pharmacother"},{"key":"9974_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/apt.12300","volume":"37","author":"LH Nguyen","year":"2013","unstructured":"Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37:921\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"9974_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S2468-1253(16)30080-2","volume":"2","author":"SG Lim","year":"2017","unstructured":"Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, et al. Management of hepatitis C virus infection in the Asia\u2013Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52\u201362.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9974_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/jgh.13709","volume":"32","author":"JH Kao","year":"2017","unstructured":"Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, et al. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol. 2017;32:966\u201374.","journal-title":"J Gastroenterol Hepatol"},{"key":"9974_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jgh.13747","volume":"32","author":"ML Yu","year":"2017","unstructured":"Yu ML, Hepatitis C. Treatment From \u201cResponse-guided\u201d to \u201cResource-guided\u201d therapy in the transition era from IFN-containing to IFN-free regimens. J Gastroenterol Hepatol. 2017;32:1436\u201342.","journal-title":"J Gastroenterol Hepatol"},{"key":"9974_CR7","unstructured":"Hospital Authority Drug Formulart (HADF). Supplementary operation guideline version 14.1 w.e.f. 14 Jul 2018. 2018 (Hong Kong)."},{"key":"9974_CR8","unstructured":"https:\/\/www.jshorjp\/files\/uploads\/HCV_GL_ver6_Dec13.pdf Accessed on 20 Sep 2018."},{"key":"9974_CR9","unstructured":"http:\/\/www.kaslorg\/guideline\/guideline_Intro.html Available on 1 Sep 2018."},{"key":"9974_CR10","unstructured":"https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D09599D25979. Accessed on 22 Feb 2019."},{"key":"9974_CR11","doi-asserted-by":"publisher","first-page":"e000207","DOI":"10.1136\/bmjgast-2018-000207","volume":"5","author":"B Wei","year":"2018","unstructured":"Wei B, Ji F, Yeo YH, Ogawa E, Zou B, Stave CD, et al. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018;5:e000207.","journal-title":"BMJ Open Gastroenterol"},{"key":"9974_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/apt.14507","volume":"47","author":"F Ji","year":"2018","unstructured":"Ji F, Wei B, Yeo YH, Ogawa E. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018;47:550\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"9974_CR13","doi-asserted-by":"publisher","first-page":"e000209","DOI":"10.1136\/bmjgast-2018-000209","volume":"5","author":"B Wei","year":"2018","unstructured":"Wei B, Ji F, Yeo YH, Ogawa E, Stave CD, Dang S, et al. Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterol. 2018;5:e000209.","journal-title":"BMJ Open Gastroenterol"},{"key":"9974_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","volume":"66","author":"SB Prenner","year":"2017","unstructured":"Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66:1173\u201381.","journal-title":"J Hepatol"},{"key":"9974_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"9974_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol int. 2017;11:317\u201370.","journal-title":"Hepatol int"},{"key":"9974_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"9974_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O","volume":"16","author":"DW Hosmer","year":"1997","unstructured":"Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16:965\u201380.","journal-title":"Stat Med"},{"key":"9974_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"9974_CR20","first-page":"2065","volume":"32","author":"J Dumortier","year":"2017","unstructured":"Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephr Dial Transpl. 2017;32:2065\u201371.","journal-title":"Nephr Dial Transpl"},{"key":"9974_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hep Int. 2016;10:702\u201326.","journal-title":"Hep Int"},{"key":"9974_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for The Study of The Liver","year":"2018","unstructured":"European Association for The Study of The Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"key":"9974_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/jech-2015-205454","volume":"70","author":"M Hellard","year":"2016","unstructured":"Hellard M, Sacks-Davis R, Doyle J. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. J Epidemiol Comm Health. 2016;70:1151\u20134.","journal-title":"J Epidemiol Comm Health"},{"key":"9974_CR24","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1136\/gutjnl-2016-311609","volume":"66","author":"TM Welzel","year":"2017","unstructured":"Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2017;66:1844\u201352.","journal-title":"Gut"},{"key":"9974_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/liv.13206","volume":"37","author":"F Tacke","year":"2017","unstructured":"Tacke F, Gunther R, Buggisch P, Klinker H, Schober A, John C, et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver int. 2017;37:205\u201311.","journal-title":"Liver int"},{"key":"9974_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/liv.13082","volume":"36","author":"JH Kao","year":"2016","unstructured":"Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver int. 2016;36:1101\u20137.","journal-title":"Liver int"},{"key":"9974_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3350\/cmh.2017.0070","volume":"24","author":"YM Kim","year":"2018","unstructured":"Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, et al. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2018;24:311\u20138.","journal-title":"Clin Mol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09974-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-019-09974-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09974-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:22:41Z","timestamp":1659097361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-019-09974-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9974"],"URL":"https:\/\/doi.org\/10.1007\/s12072-019-09974-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HT: Speaker for AbbVie and MSD. YCH: Research support from Gilead; advisory board for Gilead; speaker for Abbvie, BMS, Gilead, and Merck Sharp & Dohme. GW: Research support from Gilead; advisory board\/consulting for Gilead; speaker for Abbott, Abbvie, BMS, Echosens, Furui, and Gilead. CHL: Research support from Abbvie, Gilead, and MSD; advisory board\/consulting for Abbvie, Gilead, and MSD; speaker for Abbvie, Gilead, MSD, and Abbott. WLC: Advisory board for Gilead, Abbvie, MSD, BMS, PharmaEssentia. RC: Research support from Gilead. CYD: Advisory board for Abbvie; speaker for Abbvie, Merck, and Gilead. JHK: Research support from Gilead and BMS; advisory board\/consulting for Gilead, Abbvie, BMS, and MSD; speaker for Gilead, Abbvie, MSD, and BMS. YU: Research support from Abbvie, Gilead, and Bayer. NF: Research support from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Abbvie GK; speaker for Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Torii Pharmaceutical Co., Ltd. and Roche Diagnostics K.K. MLY: Research support: Abbvie, BMS, Gilead, Torpedo and Merck; consultant for Abbvie, Abbott, Ascletis, BMS, Gilead, Merck, and PharmaEssentia; speaker for Abbvie, Abbott, Ascletis, BMS, Gilead, and Merck. YT: Research support from Chugai Pharmaceutical, Janssen, and the Japan Agency for Medical Research and Development (AMED); honoraria from Gilead. MHN: Research support from Janssen, Pfizer, Gilead, National Cancer Institute; BK Kee Foundation; advisory board\/consulting for Novartis, Gilead, Janssen, Bayer, Eisai, Exact Sciences, Laboratory of Advanced Medicine. All other authors have no relevant conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the Helsinki Declaration of 1975, as revised in 2008, and was approved by the Institutional Review Board at Stanford University, Stanford, California, USA and participating study centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}